Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

Orazio Caffo, Giovanni Lo Re, Teodoro Sava, Sebastiano Buti, Cosimo Sacco, Umberto Basso, Fable Zustovich, Michele Lodde, Alessandra Perin, Gaetano Facchini, Antonello Veccia, Francesca Maines, Carmen Barile, Lucia Fratino, Angela Gernone, Rocco De Vivo, Giovanni L. Pappagallo, Enzo Galligioni

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: The intermittent administration of chemotherapy is a means of preserving patients' quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients' QL. Patients & methods: All patients received DOC 70 mg/m every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses. Results: The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control. Conclusion: Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients' QL.

Original languageEnglish
Pages (from-to)965-973
Number of pages9
JournalFuture Oncology
Volume11
Issue number6
DOIs
Publication statusPublished - Mar 1 2015

Keywords

  • castration-resistant prostate cancer
  • docetaxel
  • intermittent chemotherapy
  • quality of life
  • randomized trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Fingerprint Dive into the research topics of 'Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients'. Together they form a unique fingerprint.

Cite this